Zobrazeno 71 - 80
of 159
pro vyhledávání: '"Diwakar Davar"'
Autor:
Antoni Ribas, Zeynep Eroglu, Jose Manuel Manuel Trigo Perez, Brian Di Pace, Tianli Wang, Srimoyee Ghosh, Arindam Dhar, Theo Borgovan, Angela Waszak, Diwakar Davar
Publikováno v:
Journal of Clinical Oncology. 40:9513-9513
9513 Background: TIM-3 and PD-1 are markers of T-cell suppression that are upregulated in melanoma. AMBER (NCT02817633) is evaluating cobolimab (TSR-022/GSK4069889), an anti-TIM-3 therapy, monotherapy or with PD-1 inhibitors, including dostarlimab, i
Autor:
Diwakar Davar, John D. Powderly, Susanna Varkey Ulahannan, Melissa Lynne Johnson, Manish Sharma, John C. Krauss, Robert Stagg, Brian Francica, Anne Moon, Yonchu Jenkins, Peppi Prasit, Thomas Walter Dubensky, Sam H. Whiting, Kyriakos P. Papadopoulos
Publikováno v:
Journal of Clinical Oncology. 40:TPS2696-TPS2696
TPS2696 Background: Prostaglandin E2 (PGE2) is a bioactive lipid that promotes cancer through diverse mechanisms including stimulating tumor proliferation, enhancing angiogenesis and suppressing immune function in the tumor microenvironment. PGE2 pro
Autor:
Gerald Steven Falchook, Antoni Ribas, Diwakar Davar, Zeynep Eroglu, Judy S. Wang, Jason J. Luke, Erika P. Hamilton, Brian Di Pace, Tianli Wang, Srimoyee Ghosh, Arindam Dhar, Theo Borgovan, Angela Waszak, Patricia LoRusso
Publikováno v:
Journal of Clinical Oncology. 40:2504-2504
2504 Background: TIM-3 expressed on tumor-infiltrating T cells is associated with T-cell suppression. AMBER (NCT02817633) is evaluating cobolimab (TSR-022/GSK4069889) monotherapy and with PD-1 inhibitors in advanced solid tumors. Methods: Multi-cente
Autor:
Lilit Karapetyan, Arivarasan Karunamurthy, Anthony Cillo, Anjali Rohatgi, Ryan Campbell Massa, William E. Gooding, Yana G. Najjar, Diwakar Davar, Jason J. Luke, Tullia C. Bruno, Dario Vignali, John M. Kirkwood
Publikováno v:
Journal of Clinical Oncology. 40:9514-9514
9514 Background: A phase II study of nivo and rela was designed to evaluate the antitumor activity and mechanism of this combination and components for first-line treatment of pts with advanced melanoma. Pts received lead-in treatment with 1 cycle of
Autor:
Kara M. Schenk, Julie E. Stein, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I. Khushalani, Jason J. Luke, Patrick Alexander Ott, Jeffrey A. Sosman, Vikram Aggarwal, Megan Davis Schollenberger, William Howard Sharfman, Elad Sharon, Serena M. Bagnasco, Janis M. Taube, Suzanne Louise Topalian, Daniel C. Brennan, Evan J. Lipson
Publikováno v:
Journal of Clinical Oncology. 40:9507-9507
9507 Background: Cancer is a leading cause of death among KTR, but these patients (pts) have been excluded from trials of immune checkpoint inhibitors due to immunosuppression and risk of allograft loss. We report findings from the first prospective
Autor:
Heather Kelley, Rene Gonzalez, Mohammed M. Milhem, Antoni Ribas, David J. Mauro, Jason J. Luke, Aaron Morris, John M. Kirkwood, Theresa Medina, James E. Wooldridge, Bartosz Chmielowski, Arthur M. Krieg, Riyue Bao, George J. Weiner, Diwakar Davar, Katie M. Campbell, Yousef Zakharia
Publikováno v:
Cancer discovery, vol 11, iss 12
Patients with advanced melanoma that is resistant to PD-1 blockade therapy have limited treatment options. Vidutolimod (formerly CMP-001), a virus-like particle containing a CpG-A Toll-like receptor 9 (TLR9) agonist, may reverse PD-1 blockade resista
Autor:
Jeffrey E. Gershenwald, Michael T. Tetzlaff, Peter A. Prieto, Jennifer L. McQuade, Charlotte E. Ariyan, Jonathan S. Zager, David F. McDermott, Adil Daud, Christian U. Blank, Kim Margolin, Richard A. Scolyer, Brett W. Carter, Elizabeth M. Burton, Richard D. Carvajal, Jeffrey A. Sosman, Alexander N. Shoushtari, April K.S. Salama, Scott E. Woodman, Tina J. Hieken, Vernon K. Sondak, Douglas S. Tyler, Jeffrey E. Lee, Frances C. Wright, Omid Hamid, David E. Fisher, Tanja D. de Gruijl, Miles C. Andrews, Michael C. Lowe, John M. Kirkwood, Keith T. Flaherty, Mark B. Faries, Grant A. McArthur, Dirk Schadendorf, Alexander C.J. van Akkooi, Alberto Fusi, Bart A. van de Wiel, James Larkin, Ken K. Tanabe, Jane L. Messina, Jennifer A. Wargo, Rodabe N. Amaria, Jonathan Cohen, Shaneen Sandhu, Andrew J. Spillane, Reinhard Dummer, Robert Antdbacka, Michael A. Postow, Michael D. Farwell, Céleste Lebbé, Jason J. Luke, Genevieve M. Boland, Tara C. Mitchell, David H. Lawson, Elisa A. Rozeman, Diwakar Davar, Caroline Robert, Kathryn Bollin, Ryan J. Sullivan, Michael A. Davies, Matteo S. Carlino, Isabella C. Glitza, Robyn P. M. Saw, Merrick I. Ross, Axel Hauschild, Teresa M. Petrella, Paolo A. Ascierto, Serigne Lo, Igor Puzanov, Samra Turajlic, Angela Hong, Roland L. Bassett, Keith A. Delman, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Susan M. Swetter, Janis M. Taube, Alexander M.M. Eggermont, John F. Thompson, Donald A. Berry, Leslie A. Fecher, Matthew S. Block, Alexander M. Menzies, David E. Gyorki, Helen Rizos
Publikováno v:
The Lancet Oncology. 20:e378-e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of
Autor:
Andres Forero-Torres, Honey Kumar Oberoi, S. M. Ansell, Jasmine Zain, Elena Garralda, Rachel E. Sanborn, Francine M. Foss, Giuseppe Curigliano, Diwakar Davar, Anna Minchom, Vincent Ribrag, Amitkumar Mehta
Publikováno v:
Annals of Oncology. 32:S615-S616
Autor:
Diwakar Davar, Saro Sarkisian
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 12, Pp 2553-2565 (2018)
Drug Design, Development and Therapy
Drug Design, Development and Therapy
Saro Sarkisian,1 Diwakar Davar2 1Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Hematology-Oncology, Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA Abstract: Melanoma is inc
Autor:
Yana G. Najjar, Diwakar Davar, Xi Yang, Saba Shaikh, Greg M. Delgoffe, Yan Zang, Amy Rose, John M. Kirkwood, Hassane M. Zarour, Hong Wang, Jason J. Luke, Cindy Sander
Publikováno v:
Regular and young investigator award abstracts.
Background Immunotherapy has changed the treatment landscape for melanoma, although many patients (pts) do not respond to treatment. While there are likely multiple mechanisms of resistance at play, one key mechanism is the generation of an immunosup